Mani Lakshminarayanan
Overview
Explore the profile of Mani Lakshminarayanan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2024 Mar;
4(3):785.
PMID: 38477691
No abstract available.
2.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2023 Dec;
3(12):2572-2584.
PMID: 38115208
Purpose: This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ inhibitor) in combination with...
3.
Zeiser R, Socie G, Schroeder M, Abhyankar S, Vaz C, Kwon M, et al.
Lancet Haematol
. 2021 Dec;
9(1):e14-e25.
PMID: 34971577
Background: Acute graft-versus-host disease (GVHD) is a common and life-threatening complication of allogeneic haematopoietic stem cell transplantation (HSCT); there is an urgent unmet need for effective therapies. We aimed to...
4.
Garrido-Laguna I, Krop I, Burris 3rd H, Hamilton E, Braiteh F, Weise A, et al.
Int J Cancer
. 2019 Jan;
145(7):1798-1808.
PMID: 30680712
PF-06647263, a novel antibody-drug conjugate consisting of an anti-EFNA4 antibody linked to a calicheamicin payload, has shown potent antitumor activity in human xenograft tumor models, including triple-negative breast cancer (TNBC)....
5.
Gamalo-Siebers M, Gao A, Lakshminarayanan M, Liu G, Natanegara F, Railkar R, et al.
J Biopharm Stat
. 2015 Aug;
26(5):823-41.
PMID: 26247350
The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable...
6.
Ibrahim J, Chen M, Lakshminarayanan M, Liu G, Heyse J
Stat Med
. 2014 Oct;
34(2):249-64.
PMID: 25339499
Developing sophisticated statistical methods for go/no-go decisions is crucial for clinical trials, as planning phase III or phase IV trials is costly and time consuming. In this paper, we develop...
7.
Price K, Xia H, Lakshminarayanan M, Madigan D, Manner D, Scott J, et al.
Pharm Stat
. 2013 Jul;
13(1):13-24.
PMID: 23897858
Safety assessment is essential throughout medical product development. There has been increased awareness of the importance of safety trials recently, in part due to recent US Food and Drug Administration...
8.
Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, et al.
J Allergy Clin Immunol
. 2012 Oct;
130(5):1071-1077.e10.
PMID: 23036744
Background: Classifying asthma severity or activity has evolved, but there are no published weighted composite measures of asthma disease activity that account for the relative importance of the many individual...
9.
Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, et al.
Respir Med
. 2012 Feb;
106(4):500-7.
PMID: 22301379
Classifying disease activity in asthma relies on clinical and physiological variables, but these variables do not capture all aspects of asthma that distinguish levels of disease activity. We used data...
10.
Chan K, Chen W, Gan T, Hsieh R, Chen C, Lakshminarayanan M, et al.
Qual Life Res
. 2009 Oct;
18(10):1331-40.
PMID: 19876768
Purpose: To develop and validate a composite score based on clinically meaningful events (CMEs) for the opioid-related symptom distress scale (OR-SDS) that would be appropriate for use in postoperative clinical...